Browse KPNA1

Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus
Domain PF00514 Armadillo/beta-catenin-like repeat
PF16186 Atypical Arm repeat
PF01749 Importin beta binding domain
Function

Functions in nuclear protein import as an adapter protein for nuclear receptor KPNB1. Binds specifically and directly to substrates containing either a simple or bipartite NLS motif. Docking of the importin/substrate complex to the nuclear pore complex (NPC) is mediated by KPNB1 through binding to nucleoporin FxFG repeats and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to importin-beta and the three components separate and importin-alpha and -beta are re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran from importin. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus. In vitro, mediates the nuclear import of human cytomegalovirus UL84 by recognizing a non-classical NLS.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0000737 DNA catabolic process, endonucleolytic
GO:0006308 DNA catabolic process
GO:0006309 apoptotic DNA fragmentation
GO:0006310 DNA recombination
GO:0006606 protein import into nucleus
GO:0006607 NLS-bearing protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0006921 cellular component disassembly involved in execution phase of apoptosis
GO:0017038 protein import
GO:0019048 modulation by virus of host morphology or physiology
GO:0019054 modulation by virus of host process
GO:0019058 viral life cycle
GO:0019439 aromatic compound catabolic process
GO:0030262 apoptotic nuclear changes
GO:0034504 protein localization to nucleus
GO:0034655 nucleobase-containing compound catabolic process
GO:0035821 modification of morphology or physiology of other organism
GO:0044003 modification by symbiont of host morphology or physiology
GO:0044068 modulation by symbiont of host cellular process
GO:0044270 cellular nitrogen compound catabolic process
GO:0044744 protein targeting to nucleus
GO:0044766 multi-organism transport
GO:0046700 heterocycle catabolic process
GO:0046794 transport of virus
GO:0051052 regulation of DNA metabolic process
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051701 interaction with host
GO:0051817 modification of morphology or physiology of other organism involved in symbiotic interaction
GO:0075733 intracellular transport of virus
GO:0090305 nucleic acid phosphodiester bond hydrolysis
GO:0097194 execution phase of apoptosis
GO:1901361 organic cyclic compound catabolic process
GO:1902579 multi-organism localization
GO:1902581 multi-organism cellular localization
GO:1902583 multi-organism intracellular transport
GO:1902593 single-organism nuclear import
Molecular Function GO:0005048 signal sequence binding
GO:0008139 nuclear localization sequence binding
GO:0008565 protein transporter activity
GO:0033218 amide binding
GO:0042277 peptide binding
Cellular Component GO:0005635 nuclear envelope
GO:0005643 nuclear pore
GO:0030425 dendrite
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-168276: NS1 Mediated Effects on Host Pathways
R-HSA-211227: Activation of DNA fragmentation factor
R-HSA-1169410: Antiviral mechanism by IFN-stimulated genes
R-HSA-109581: Apoptosis
R-HSA-140342: Apoptosis induced DNA fragmentation
R-HSA-75153: Apoptotic execution phase
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1643685: Disease
R-HSA-162594: Early Phase of HIV Life Cycle
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-162909: Host Interactions of HIV factors
R-HSA-168253: Host Interactions with Influenza Factors
R-HSA-1169408: ISG15 antiviral mechanism
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-162592: Integration of provirus
R-HSA-176033: Interactions of Vpr with host cellular proteins
R-HSA-913531: Interferon Signaling
R-HSA-5357801: Programmed Cell Death
R-HSA-168271: Transport of Ribonucleoproteins into the Host Nucleus
R-HSA-180910: Vpr-mediated nuclear import of PICs
Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KPNA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KPNA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.57 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KPNA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0060.979
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3520.833
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2440.835
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1650.585
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0810.967
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2730.914
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.10.817
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1550.932
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0180.993
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5220.695
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.6280.375
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0350.47
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KPNA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KPNA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KPNA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KPNA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KPNA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KPNA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KPNA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKPNA1
Namekaryopherin alpha 1 (importin alpha 5)
Aliases RCH2; NPI-1; IPOA5; RAG cohort protein 2; SRP1-beta; importin alpha 5; importin-alpha-S1; karyopherin subuni ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KPNA1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.